"We Envision Growth Strategies Most Suited
to Your Business"

Immunology Market to Reach $158.69 Billion by 2028; Stoked by Increasing Prevalence of Autoimmune Disorders Worldwide

June 10, 2021 | Healthcare

The global immunology market size is expected to gain momentum by reaching USD 158.69 billion by 2028. This information is published by Fortune Business Insights in its report, titled “Immunology Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibody (pAb), and Others); By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, and Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Regional Forecast, 2021-2028.” The report further mentions that the market stood at USD 85.74 billion in 2020 and is likely to exhibit a CAGR of 8.1% between 2021 and 2028.

The U.S. FDA Approves STELARA by Janssen to Treat Pediatric Psoriasis

In July 2020, Janssen Pharmaceuticals, a part of Johnson & Johnson, announced that it has secured approval from the U.S. Food and Drug Administration (FDA) for its effective drug, STELARA. The company reports that the drug is effective in treating pediatric psoriasis and its administration brings relief for patients suffering from skin plaques or lesions. The drug targets both the interleukin IL-23 and IL-12 that is responsible for modulating the overactive inflammatory response in several autoimmune disorders. STELARA can be administered through injection four times a year after the initial two starter doses. The approval is expected to positively impact the sales revenue of the company that is highly focused on delivering meaningful immunology solutions for the patients.  

To get a detailed report summary and research scope of this market, click here:


Increasing Prevalence of Autoimmune Diseases to Propel Market Growth

According to a research article by the National Stem Cell Foundation, around 4% of the global population suffers from at least one of 80 different autoimmune diseases annually. The increasing prevalence of autoimmune diseases due to several factors such as stress, gut dysbiosis, dietary components, and others is driving the attention of the manufacturers to develop advanced drug solutions to combat the disorders. For instance, in September 2020, Lupin announced the launch of a generic rheumatoid arthritis drug, Leflunomide, in the U.S. Therefore, these factors are expected to contribute to the global market growth in the forthcoming years.

Collaboration between Prominent Companies to Expand Their Product Portfolio and Boost Sales Revenue

The market comprises small, medium, and large companies striving to maintain a stronghold by collaborating with other companies to develop advanced immunology drug solutions to cater to the rising healthcare industry’s demand. Besides, other key players are further adopting organic and inorganic growth strategies such as merger and acquisition, partnership, and facility expansion to maintain their footprint in the fiercely competitive global marketplace.

List of the Companies Profiled in the Global Market:

  • Pfizer Inc. (New York, U.S.)

  • F. Hoffmann-La Roche Ltd. (Basel, Switzerland)

  • AbbVie, Inc. (North Chicago, U.S.)

  • Bristol-Myers Squibb Company (New York City, U.S.)

  • Merck Sharp & Dohme Corp. (New Jersey, U.S.)

  • Novartis AG (Basel, Switzerland)

  • Janssen Global Services, LLC (Raritan, New Jersey, U.S.)

  • Amgen Inc. (California, U.S.)

  • Astellas Pharma Inc. (Tokyo, Japan)

  • UCB SA (Brussels, Belgium)

  • Eli Lilly and Company (Indianapolis, U.S.)

  • Other Prominent Players

Further Report Findings:

  • North America stood at USD 46.17 billion in 2020 and is expected to hold the largest global immunology market share in the forthcoming years. This is ascribable to factors such as the presence of well-established healthcare infrastructure and the rising treatment rate among patients in countries such as the U.S. in the region.

  • The market in Europe is expected to showcase significant growth backed by the increasing drug approvals and the higher prevalence of autoimmune disorders that is propelling the demand for advanced immunology drugs in the region between 2021 and 2028.

  • Asia-Pacific is anticipated to experience considerable growth during the forecast period. This is owing to the high demand for preventive care in countries such as India and China that will propel the demand for advanced immunology drugs and therapies.

  • Based on drug class, the monoclonal antibody (mAb) segment is expected to showcase exponential growth due to the high clinical efficacy of the monoclonal antibodies in treating chronic ailments worldwide. The segment held a market share of about 64.5% in 2020.

Table of Segmentation:



Study Period


Base Year


Forecast Period


Historical Period



  Value (USD billion)


By Drug Class

  • Monoclonal antibody (mAb)

  • Fusion Proteins

  • Immunosuppressants

  • Polyclonal antibody (pAb)

  • Others

By Disease Indication

  • Rheumatoid Arthritis

  • Psoriatic Arthritis

  • Plaque Psoriasis

  • Ankylosing Spondylitis

  • Inflammatory Bowel Disease

  • Prophylaxis of Organ Rejection

  • Others

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies


By Geography

  • North America (U.S. and Canada)

  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

  • Latin America (Brazil, Mexico, Rest of Latin America)

  • The Middle East & Africa (GCC, South Africa, Rest of the Middle East & Africa)

Immunology Market
  • PDF
  • 2020
  • 2017-2019
  • 149


  • 4850

Our Clients

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.